Assistant or Associate Professor, Oncology (Myeloma BMT / IMTX)
Fred Hutchinson Cancer Research Center
Location: Seattle, WA
Internal Number: 91346
Blood and Marrow Transplant and Immunotherapy Programs – Myeloma focus. Clinician Scholar pathway with an approximate 50:50 contribution to clinical service and academic pursuits.
The Fred Hutchinson Cancer Center (Fred Hutch) and the University of Washington (UW) are jointly recruiting a full-time faculty member at the Assistant Professor or Associate Professor level without tenure due to funding (WOT), commensurate with experience and qualifications in the Clinical Research Division of the Fred Hutch and the Division of Medical Oncology, Department of Medicine at the UW. This position would have an annual service period of 12 months [July 1-June 30]. The primary appointment will be in the Clinical Research Division of Fred Hutch. The selected individual for the advertised position is expected to contribute to our mission of delivering outstanding clinical care and developing excellence in clinical research in transplantation and immunotherapy. All clinical and translational research experiences and interests will be considered and a specific interest and experience in the field of autologous transplantation and/or immunotherapy for patients with multiple myeloma is highly desirable. Fred Hutch and University of Washington faculty engage in teaching, research, and service. Teaching responsibilities will involve oversight of advanced practice providers and fellows during inpatient and outpatient rotations, and delivery of informal teaching sessions and formal lectures to providers and the general medical community.
Fred Hutch is an independent, nonprofit, unified adult cancer care and research center that is clinically integrated with UW Medicine, a world leader in clinical care, research and learning. The first National Cancer Institute-designated cancer center in the Pacific Northwest, Fred Hutch's global leadership in bone marrow transplantation, HIV/AIDS prevention, immunotherapy, and COVID-19 vaccines has confirmed our reputation as one of the world's leading cancer, infectious disease and biomedical research centers. Based in Seattle, Fred Hutch operates eight clinical care sites that provide medical oncology, infusion, radiation, proton therapy, and related services, and network affiliations with hospitals in five states. Together, our fully integrated research and clinical care teams seek to discover new cures to the world's deadliest diseases and make life beyond cancer a reality.
At Fred Hutch, we believe that the innovation, collaboration, and rigor that result from diversity and inclusion are critical to our mission of eliminating cancer and related diseases. We seek employees who bring different and innovative ways of seeing the world and solving problems. Fred Hutch is in pursuit of becoming an antiracist organization. We are committed to ensuring that all candidates hired share our commitment to diversity, antiracism, and inclusion.
The ideal candidate should have a record of and primary interest in hematopoietic cell transplantation as well as an active clinical research interest, as demonstrated by peer-reviewed publications, in the application of transplantation to the treatment of human disease.
Applicants must have an MD/DO degree (or foreign equivalent) and board certification in Medical Oncology or Hematology (or foreign equivalent). In order to be eligible for University sponsorship for an H-1B visa, graduates of foreign (non-U.S.) medical schools must show successful completion of all three steps of the U.S. Medical Licensing Exam (USMLE) or equivalent as determined by the Secretary of Health and Human Services.
Interested candidates should submit a curriculum vitae, a concise statement of career goals including a description of clinical research goals and a diversity statement describing your past contributions to diversity, equity, and inclusion and your future plans for continuing these efforts (two pages or less), and a list of five (5) references, along with a letter of application addressed to: Dr. Marco Mielcarek.
University of Washington is an affirmative action and equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, creed, religion, national origin, sex, sexual orientation, marital status, pregnancy, genetic information, gender identity or expression, age, disability, or protected veteran status.
Fred Hutch is proud to be an Equal Employment Opportunity (EEO) and Vietnam Era Veterans Readjustment Assistance Act (VEVRAA) Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability (physical or mental), marital or veteran status, genetic information, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. If due to a disability you need assistance/and or a reasonable accommodation during the application or recruiting process, please send a request to our Employee Services Center at email@example.com or by calling 206-667-4700.
At Fred Hutchinson Cancer Research Center, teams of world-renowned scientists and humanitarians work together to prevent, diagnose and treat cancer, HIV/AIDS and other diseases. Researchers are discovering new ways to detect cancers earlier, improve treatments, and learn how to prevent cancers from growing. Although Fred Hutchinson opened its doors in 1975, its history began about 20 years before that. In 1962 Fred Hutchinson envisioned a center devoted to studying cancer, a disease that took his brother’s life. Today Fred Hutchinson is contributing to the next waves of breakthrough treatments and prevention strategies. Fred Hutchinson collaborates with the Seattle Cancer Alliance, the National Cancer Institute, and the University of Washington.